835 reports of this reaction
3.0% of all LEDIPASVIR AND SOFOSBUVIR reports
#7 most reported adverse reaction
INSOMNIA is the #7 most commonly reported adverse reaction for LEDIPASVIR AND SOFOSBUVIR, manufactured by Gilead Sciences, Inc. There are 835 FDA adverse event reports linking LEDIPASVIR AND SOFOSBUVIR to INSOMNIA. This represents approximately 3.0% of all 27,933 adverse event reports for this drug.
Patients taking LEDIPASVIR AND SOFOSBUVIR who experience insomnia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INSOMNIA is a less commonly reported adverse event for LEDIPASVIR AND SOFOSBUVIR, but still significant enough to appear in the safety profile.
In addition to insomnia, the following adverse reactions have been reported for LEDIPASVIR AND SOFOSBUVIR:
The following drugs have also been linked to insomnia in FDA adverse event reports:
INSOMNIA has been reported as an adverse event in 835 FDA reports for LEDIPASVIR AND SOFOSBUVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
INSOMNIA accounts for approximately 3.0% of all adverse event reports for LEDIPASVIR AND SOFOSBUVIR, making it a notable side effect.
If you experience insomnia while taking LEDIPASVIR AND SOFOSBUVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.